ABSTRACT
OBJECTIVE: To analyze the prevalence, severity and functional interference of movement disorders (MD) secondary to chronic use of cyclosporine A (CsA). METHOD: We conducted a cross-sectional study of 60 patients (58.3% male) with mean age 23.1 (3-75) years, followed at the Bone Marrow Transplantation Service of the Hospital de Clínicas of the Federal University of Paraná, Brazil, taking CsA for at least six months. Our protocol included clinical data, assessment of functional interference of symptoms and neurological examination including observation and grading of MD. RESULTS: Eight (13.3%) subjects reported the presence of tremor at the moment of interview and 29 (48.3%) recalled this symptom at some point during treatment. Neurological examination identified 14 (23.3%) subjects with MD: upper limb symmetric action tremor in 13 (21.6%) and parkinsonism (rigidity and bradykinesia) in 1 (1.7%). No other MD was detected. The mean scores indicated mild clinical signs in all cases. Symptoms were considered subjectively mild with no functional interference. CONCLUSION: Almost one quarter of patients using CsA chronically presented MD, almost always mild and transitory action tremor, with minimal interference on daily living activities, not requiring any form of intervention in the majority of cases.
Subject(s)
Bone Marrow Transplantation , Cyclosporine/adverse effects , Dyskinesia, Drug-Induced/epidemiology , Immunosuppressive Agents/adverse effects , Adult , Aged , Child , Child, Preschool , Cross-Sectional Studies , Cyclosporine/therapeutic use , Dyskinesia, Drug-Induced/diagnosis , Female , Graft Rejection/prevention & control , Humans , Immunosuppressive Agents/therapeutic use , Interviews as Topic , Long-Term Care , Male , Middle Aged , Neurologic Examination , Prevalence , Severity of Illness IndexABSTRACT
OBJETIVO: Analisar a prevalência, gravidade e interferência funcional de transtornos do movimento (TM) secundários ao uso crônico de ciclosporina A (CsA). MÉTODO: Realizamos um estudo transversal em 60 pacientes (58.3% do sexo masculino) com idade média de 23.1 (3-75) anos, acompanhados pelo Serviço de Transplante de Medula Óssea do Hospital de Clínicas da Universidade Federal do Paraná, usando CsA por pelo menos seis meses. A avaliação incluiu dados clínicos, interferência funcional de possíveis sintomas e exame neurológico incluindo observação e graduação de TM. RESULTADOS: Oito (13.3%) entrevistados relataram tremor no momento da entrevista e 29 (48.3%) em alguma fase do tratamento. O exame neurológico identificou 14 (23.3%) pacientes com TM: 13 (21.6%) tremor de ação simétrico de membros superiores e em 1 (1.7%) parkinsonismo (rigidez e bradicinesia). Nenhum outro TM foi detectado. Os escores médios indicaram quadros leves em todos os casos. Os sintomas foram também considerados subjetivamente leves e sem interferência funcional. CONCLUSÃO: Quase um quarto dos pacientes usando CsA cronicamente apresenta TM, quase sempre tremor de ação leve e transitório, interferindo pouco funcionalmente, não requerendo intervenção na maioria dos casos.
Subject(s)
Adult , Aged , Child , Child, Preschool , Female , Humans , Male , Middle Aged , Bone Marrow Transplantation , Cyclosporine/adverse effects , Dyskinesia, Drug-Induced/epidemiology , Immunosuppressive Agents/adverse effects , Cross-Sectional Studies , Cyclosporine/therapeutic use , Dyskinesia, Drug-Induced/diagnosis , Graft Rejection/prevention & control , Interviews as Topic , Immunosuppressive Agents/therapeutic use , Long-Term Care , Neurologic Examination , Prevalence , Severity of Illness IndexABSTRACT
We report a case of Fanconi anemia in which cytogenetic analysis of bone marrow (BM) samples revealed two distinct karyotypes: 46,XY,dup(1)(q21q42), in the first sample and 46,XY,del(1)(q32) in the second, aspirated 7 months later after acute myeloid leukemia (AML) developed. We discuss the cytogenetic clonal fluctuation common in Fanconi anemia, with the Fanconi's anemia (FA) reports available in the literature. Interestingly, we have identified that del(1)(q32) has not been reported before in FA.
Subject(s)
Bone Marrow/pathology , Chromosome Aberrations , Chromosomes, Human, Pair 1/genetics , Fanconi Anemia/genetics , Leukemia, Myeloid/genetics , Acute Disease , Child , Chromosome Deletion , Fanconi Anemia/complications , Fanconi Anemia/pathology , Humans , Karyotyping , Leukemia, Myeloid/complications , Leukemia, Myeloid/pathology , MaleABSTRACT
Reversible posterior leucoencephalopathy syndrome (RPLS) has previously been described in patients who have renal insufficiency, eclampsia, hypertensive encephalopathy and patients receiving immunosuppressive therapy. The mechanism by which immunosuppressive agents can cause this syndrome is not clear, but it is probably related with cytotoxic effects of these agents on the vascular endothelium. We report eight patients who received cyclosporine A (CSA) after allogeneic bone marrow transplantation or as treatment for severe aplastic anemia (SSA) who developed posterior leucoencephalopathy. The most common signs and symptoms were seizures and headache. Neurological dysfunction occurred preceded by or concomitant with high blood pressure and some degree of acute renal failure in six patients. Computerized tomography studies showed low-density white matter lesions involving the posterior areas of cerebral hemispheres. Symptoms and neuroimaging abnormalities were reversible and improvement occurred in all patients when given lower doses of CSA or when the drug was withdrawn. RPLS may be considered an expression of CSA neurotoxicity
